A physician-reviewed comparison hub covering the main alternatives to Ozempic — Wegovy, Mounjaro, Zepbound, compounded semaglutide, compounded tirzepatide, Rybelsus, and Saxenda — with active ingredient, mechanism, FDA indication, and monthly cost side by side.
The main alternatives to Ozempic are compounded semaglutide, Wegovy, Mounjaro, Zepbound, compounded tirzepatide, Rybelsus, and Saxenda. For most self-pay patients the practical comparison is brand-name Ozempic (~$970/mo list) versus compounded semaglutide (from $96/mo via telehealth), since both use the same active ingredient. Patients seeking a stronger appetite and metabolic effect often move to tirzepatide (Mounjaro, Zepbound, or compounded), which activates both the GLP-1 and GIP receptors.
Compounded Semaglutide — Active ingredient: semaglutide. Mechanism: GLP-1 receptor agonist. Delivery: once-weekly subcutaneous vial + syringe. Not FDA-approved; compounded under physician prescription. Cost: $96–$299/mo via telehealth (Astra from $96/mo on the 6-month plan). Telehealth Rx via 503A licensed compounding pharmacy.
Ozempic — Active ingredient: semaglutide. Mechanism: GLP-1 receptor agonist. Delivery: once-weekly subcutaneous pen. FDA indication: type 2 diabetes; used off-label for weight loss. Cost: ~$970/mo list, ~$0–$25 with commercial insurance. Prescription pathway: brand-name Rx, frequent shortages on FDA drug list.
Wegovy — Active ingredient: semaglutide. Mechanism: GLP-1 receptor agonist. Delivery: once-weekly subcutaneous pen. FDA indication: chronic weight management (BMI ≥30, or ≥27 with comorbidity). Cost: ~$1,349/mo list; NovoCare self-pay from $349/mo. Prescription pathway: brand-name Rx; NovoCare direct program available.
Mounjaro — Active ingredient: tirzepatide. Mechanism: dual GLP-1 / GIP receptor agonist. Delivery: once-weekly subcutaneous pen. FDA indication: type 2 diabetes; used off-label for weight loss. Cost: ~$1,080/mo list, ~$0–$25 with commercial insurance. Brand-name Rx.
Zepbound — Active ingredient: tirzepatide. Mechanism: dual GLP-1 / GIP receptor agonist. Delivery: once-weekly subcutaneous pen or vial. FDA indication: chronic weight management (BMI ≥30, or ≥27 with comorbidity); obstructive sleep apnea. Cost: ~$1,086/mo list; LillyDirect vials $299–$449/mo. Brand-name Rx; LillyDirect self-pay available.
Compounded Tirzepatide — Active ingredient: tirzepatide. Mechanism: dual GLP-1 / GIP receptor agonist. Delivery: once-weekly subcutaneous vial + syringe. Not FDA-approved; compounded under physician prescription. Cost: $125–$399/mo via telehealth (Astra from $125/mo on the annual plan). Telehealth Rx via 503A licensed compounding pharmacy.
Rybelsus — Active ingredient: oral semaglutide. Mechanism: GLP-1 receptor agonist. Delivery: daily oral tablet. FDA indication: type 2 diabetes. Cost: ~$1,000/mo list; commercial insurance often covers. Brand-name Rx.
Saxenda — Active ingredient: liraglutide. Mechanism: GLP-1 receptor agonist. Delivery: once-daily subcutaneous pen. FDA indication: chronic weight management (adults and adolescents ≥12). Cost: ~$1,349/mo list; NovoCare programs available. Brand-name Rx.
Which alternative is right for you: If insurance covers Ozempic or Wegovy, the brand-name path is usually lowest out-of-pocket ($0–$25 copay). If self-pay and cost is the constraint, compounded semaglutide via a licensed telehealth pharmacy is typically the lowest-price path. If seeking stronger appetite and metabolic effect, tirzepatide has shown larger average weight reductions in clinical trials than semaglutide. If preferring oral over injection, Rybelsus is oral semaglutide taken daily. If currently on Ozempic and running into shortages, a clinician can evaluate switching to Wegovy, tirzepatide, or a compounded alternative under supervision.
FAQ — What is the best alternative to Ozempic? It depends on the goal: Wegovy and Zepbound are the FDA-approved weight-management alternatives; compounded semaglutide (from $96/mo) is the lowest-cost self-pay path; tirzepatide targets both GLP-1 and GIP receptors for a stronger effect.
FAQ — Is compounded semaglutide the same as Ozempic? Both contain semaglutide as the active pharmaceutical ingredient, but they are not the same product. Ozempic is FDA-approved and manufactured by Novo Nordisk in a fixed-dose pen. Compounded semaglutide is prepared by licensed US 503A compounding pharmacies under a physician prescription, is not FDA-approved as a finished drug, and is delivered as a vial with syringes.
FAQ — Is it legal to get an Ozempic alternative online? Yes. Telehealth providers licensed in your state can prescribe GLP-1 medications after a medical evaluation. Compounded semaglutide and tirzepatide are legally dispensed by 503A licensed compounding pharmacies under a valid US physician prescription.
FAQ — Which is cheaper, Ozempic or compounded semaglutide? Compounded semaglutide is substantially cheaper for self-pay patients. Ozempic lists at roughly $970/mo without insurance; compounded semaglutide through telehealth ranges from about $96/mo (Astra, 6-month plan) to $299/mo depending on provider and plan.
FAQ — Semaglutide vs. tirzepatide difference: semaglutide (Ozempic, Wegovy, Rybelsus, compounded) activates the GLP-1 receptor. Tirzepatide (Mounjaro, Zepbound, compounded) activates both GLP-1 and GIP receptors. Tirzepatide has produced larger average weight reductions than semaglutide in head-to-head trials.
FAQ — Can I switch from Ozempic to a compounded alternative? Switching is common during insurance changes or shortages but should always be done under physician supervision, since dose equivalents and titration schedules differ between formulations.
FAQ — Are compounded GLP-1s safe? When prescribed by a licensed physician and dispensed by a 503A pharmacy operating under state and federal compounding regulations, compounded GLP-1s are used under clinical oversight. They are not FDA-approved as finished products.
FAQ — Do Ozempic alternatives require a prescription? Yes. Every GLP-1 medication requires a valid prescription from a licensed US clinician following a medical evaluation.
Sources: FDA Ozempic (semaglutide) prescribing information; FDA Wegovy prescribing information; FDA tirzepatide (Mounjaro / Zepbound) drug approval; FDA compounding and the FDA questions and answers; NIH review of GLP-1 receptor agonists for weight management; NEJM SURMOUNT-1 tirzepatide once-weekly for treatment of obesity; NEJM STEP-1 once-weekly semaglutide in adults with overweight or obesity.
Astra's clinical care is delivered by Wasef Health, PC and VialsRx, a licensed 503A US compounding pharmacy. This page is informational and not medical advice. Compounded medications are not FDA-approved. Prices verified July 2026 and may have changed. Data on this page may be reused with attribution to Astra Health (CC BY 4.0). CSV available at /ozempic-alternatives.csv; JSON at /ozempic-alternatives.json.